Scientists reported that fibrinogen-like protein 1, a newly identified immune checkpoint ligand, was modified by acetylation at Lys 98 in HCC, which targeted it for proteasomal degradation.
[Journal Of Clinical Investigation]
Targeting Fibrinogen-Like Protein 1 Enhances Immunotherapy in Hepatocellular Carcinoma
